Last reviewed · How we verify
Investigational Tdap vaccine Formulation B
Investigational Tdap vaccine Formulation B is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 1 development.
At a glance
| Generic name | Investigational Tdap vaccine Formulation B |
|---|---|
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational Tdap vaccine Formulation B CI brief — competitive landscape report
- Investigational Tdap vaccine Formulation B updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Investigational Tdap vaccine Formulation B
What is Investigational Tdap vaccine Formulation B?
Investigational Tdap vaccine Formulation B is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes Investigational Tdap vaccine Formulation B?
Investigational Tdap vaccine Formulation B is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
What development phase is Investigational Tdap vaccine Formulation B in?
Investigational Tdap vaccine Formulation B is in Phase 1.